목적: To reduce toxicities of cisplatin-based intraperitoneal (IP) chemotherapy, cisplatin was substituted with carboplatin. We compared toxicities and long term survival outcomes of carboplatin- and cisplatin-based IP chemotherapy in advanced epithelial ovarian cancer. 방법: We conducted a retrospective study of patients receiving carboplatin-based (n=21, IP carboplatin AUC 5 on Day 1, IV paclitaxel 175mg/m2 on Day 2, and IP paclitaxel 60mg/m2 on Day 8) and cisplatin-based IP chemotherapy (n=16, IV paclitaxel 135mg/m2 on Day 1, IP cisplatin 100mg/m2 on Day 2, and IP paclitaxel 60mg/m2 on Day 8) after primary surgery for epithelial ovarian cancer (EOC) at Severance Hospital between Jan 2006 and Jun 2009. Toxicity data in a total of 210 cycles of IP chemotherapy were analyzed and survival data in each group was compared. 결과: There was significantly more grade 3 granulocytopenia (56.2%vs23.8%, p=0.044) and leukopenia (62.5%vs23.8%, p=0.018) in the IP cisplatin group. Patients treated with cisplatin based IP chemotherapy were more likely to suffer from chemotherapy related grade 2 or 3 nausea/vomiting (75.0%vs19.0%, p=0.001), abdominal pain (62.5%vs23.8%, p=0.018), hepatotoxicity (43.8%vs9.5%, p=0.016) and neuromuscular effects (56.2%vs19.0%, p=0.019). The proportion of patients who received 6 or more cycles in carboplatin based IP chemotherapy group was significantly higher than that in cisplatin based IP chemotherapy group (82.4%vs50.0%, p=0.049). Median progression-free survival (PFS) and overall survival (OS) in patients with FIGO stage 3, 4 were 19 and 50 in carboplatin group and 22 and 90 in cisplatin group. We found no significant between-group differences in PFS and OS (p=0.249 and 0.252). 결론: Carboplatin based IP chemotherapy is an acceptable alternative to cisplatin based IP chemotherapy for EOC. With the potential advantages of carboplatin based IP chemotherapy in the view of toxicity, carboplatin based IP chemotherapy may have an impact on the therapeutic strategy of EOC.